Libo Tang
Overview
Explore the profile of Libo Tang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gu S, Tang L, Guo L, Zhong C, Fu X, Ye G, et al.
Emerg Microbes Infect
. 2024 Oct;
13(1):2409350.
PMID: 39470771
It is well established that humoral immunity targeting hepatitis B virus surface antigen (HBsAg) plays a critical role in viral clearance and clinical cure. However, the functional changes in HBsAg-specific...
2.
Tang L, Li R, Wen H, Zhou Q, Xu C
Chin Med J Pulm Crit Care Med
. 2024 Aug;
1(4):207-214.
PMID: 39171282
Lung cancer is the second most common cancer worldwide and the leading cause of cancer-related fatalities, with non-small cell lung cancer (NSCLC) accounting for 85% of all lung cancers. Over...
3.
Ye G, Chen C, Zhou Y, Tang L, Cai J, Huang Y, et al.
Antiviral Res
. 2024 Aug;
230:105975.
PMID: 39089333
Background: Hepatitis B core antibody (anti-HBc) is commonly present in patients with chronic hepatitis B virus (HBV) infection and serves as a marker of humoral immunity. Herein, we aim to...
4.
Chen P, Dong Z, Zhu W, Chen J, Zhou Y, Ye Q, et al.
Hepatology
. 2023 Oct;
80(2):330-345.
PMID: 37820061
Background And Aims: Cancer stem cells (CSCs) contribute to therapy resistance in HCC. Linear ubiquitin chain assembly complex (LUBAC) has been reported to accelerate the progression of cancers, yet its...
5.
Tang L, Li Q, Chen L, Li X, Gu S, He W, et al.
J Med Virol
. 2023 Oct;
95(10):e29142.
PMID: 37815034
Available therapies for chronic hepatitis B virus (HBV) infection are not satisfying, and interleukin-21 (IL-21) and checkpoint inhibitors are potential therapeutic options. However, the mechanism underlying IL-21 and checkpoint inhibitors...
6.
Han X, Zhou C, Luo X, Pang H, Han C, Tang L, et al.
Curr Mol Med
. 2023 Jun;
24(5):648-666.
PMID: 37312441
Introduction: This study implies the enhancement of apatinib killing effect in 4T1 tumor cells through constructing drug-loaded nanoparticles apatinib/Ce6@ZIF- 8@Membranes (aCZM) to enhance tumor therapeutic targeting and reduce toxic side...
7.
Liu Z, Song L, Chen J, Zhou Y, Wang Y, Tang L, et al.
Virol J
. 2023 Jun;
20(1):109.
PMID: 37264390
Background: The relationship between chronic hepatitis B (CHB) and Coronavirus disease 2019 (COVID-19) has been inconsistent in traditional observational studies. Methods: We explored the total causal and direct causal associations...
8.
Li Y, Zhong S, Jin Z, Ye G, Zhang T, Liu Z, et al.
Virus Res
. 2023 May;
331:199129.
PMID: 37160233
Background: Gut microbiota is crucial for immune homeostasis and is associated with the prognosis of chronic hepatitis B infection. Peyer's patches (PPs), characterized by intestinal mucosa localization, are involved in...
9.
Wen C, Zhou Y, Zhou Y, Wang Y, Dong Z, Gu S, et al.
Antiviral Res
. 2023 Mar;
213:105585.
PMID: 36963665
Background & Aims: Treatment with nucleos(t)ide analogue (NA) efficiently suppresses viral replication in patients with chronic HBV infection, yet HBV relapses frequently upon NA withdrawal; the detailed immunomodulatory compounds for...
10.
Li Y, Wen C, Gu S, Wang W, Guo L, Li C, et al.
Hepatology
. 2023 Mar;
78(2):592-606.
PMID: 36896974
Background And Aim: Long-term maintenance of viral control, even HBsAg loss, remains a challenge for chronic hepatitis B (CHB) patients undergoing nucleos(t)ide analogue (NA) discontinuation. This study aimed to investigate...